 |
Top 10 Brain Regeneration startups
Updated: April 19, 2024 |
These startups develop new diagnostic methods and treatments for brain diseases and traumas. The also create brain regeneration technologies for brain dementia.
1
Country: USA | Funding: $622M
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Country: USA | Funding: $612M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
3
Country: USA | Funding: $487.2M
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology.
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology.
4
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
5
Country: USA | Funding: $409M
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
6
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
7
Country: USA | Funding: $373.4M
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
8
Country: USA | Funding: $273.9M
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
9
Country: Canada | Funding: $225M
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
10
Country: USA | Funding: $225M
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
11
Country: USA | Funding: $221M
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
12
Country: USA | Funding: $194.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
13
Country: USA | Funding: $140M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
14
Country: USA | Funding: $140M
Capsida develops targeted gene therapies in serious neurodegenerative diseases.
Capsida develops targeted gene therapies in serious neurodegenerative diseases.
15
Country: USA | Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
16
Country: USA | Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
17
Country: USA | Funding: $133.8M
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
18
Country: USA | Funding: $110M
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
19
Country: Denmark | Funding: $77.9M
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
20
Country: Israel | Funding: $65.5M
Brainsway has revolutionized brain disorder treatment, with Brainsway Deep TMS therapy, or Deep Transcranial Magnetic Stimulation. With Brainsway Deep TMS, patients can regain wellbeing, calm and happiness in just a few weeks.
Brainsway has revolutionized brain disorder treatment, with Brainsway Deep TMS therapy, or Deep Transcranial Magnetic Stimulation. With Brainsway Deep TMS, patients can regain wellbeing, calm and happiness in just a few weeks.
21
Country: Israel | Funding: $59.1M
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
22
Country: Israel | Funding: $48.5M
ElMindA revolutionizing the management of brain disorders and injuries, by transforming state of the art neuroscience into bed-side clinical practice, opening a new window into our brain’s functionality, and enabling well-informed clinical decision making.
ElMindA revolutionizing the management of brain disorders and injuries, by transforming state of the art neuroscience into bed-side clinical practice, opening a new window into our brain’s functionality, and enabling well-informed clinical decision making.
23
Country: Israel | Funding: $48.8M
BrainQ is developing Artificial Intelligence-powered technologies to treat neuro-disorders in innovative ways.
BrainQ is developing Artificial Intelligence-powered technologies to treat neuro-disorders in innovative ways.
24
Country: USA | Funding: $41.3M
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
25
Country: UK | Funding: $40.3M
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
26
Country: South Korea | Funding: ₩48B
NEUROPHET is a medical SW company using advanced neuroscience and AI technologies for better brain treatment.
NEUROPHET is a medical SW company using advanced neuroscience and AI technologies for better brain treatment.
27
Country: USA | Funding: $30M
Constant Therapy is developing a mobile app designed to provide therapy to patients who have traumatic brain injury, stroke, aphasia, and learning disabilities.
Constant Therapy is developing a mobile app designed to provide therapy to patients who have traumatic brain injury, stroke, aphasia, and learning disabilities.
28
Country: Canada | Funding: $25.2M
Optina Diagnostics develops technology for the early detection of disease through the eye.
Optina Diagnostics develops technology for the early detection of disease through the eye.
29
Country: USA | Funding: $24.7M
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
30
Country: UK
Magstim has always been at the cutting edge of the evolution of transcranial magnetic stimulation (TMS) from its conception as a valuable research tool to its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD).
Magstim has always been at the cutting edge of the evolution of transcranial magnetic stimulation (TMS) from its conception as a valuable research tool to its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD).
31
Country: UK | Funding: $20M
Oxford Endovascular are developing a novel treatment for treating brain aneurysms.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms.
32
Country: USA | Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
33
Country: USA
Exploring the potential of cutting edge biomedical technology for human neuro-regeneration and neuro-reanimation. Our definitions of death, specifically the death of the human brain, may have to change in the very near future.
Exploring the potential of cutting edge biomedical technology for human neuro-regeneration and neuro-reanimation. Our definitions of death, specifically the death of the human brain, may have to change in the very near future.
34
Country: USA | Funding: $14.4M
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
35
Country: South Korea | Funding: $13.4M
Through use of technology in which measures and modulates brain signals, we develop research protocols that improve cognitive functions. We provide meaningful information retrieved from the wearable devices through analysis of brain signal big data. With this big data, we predict and diagnose the stages of the neurological diseases such as Alzheimer’s disease and mild cognitive impairment.
Through use of technology in which measures and modulates brain signals, we develop research protocols that improve cognitive functions. We provide meaningful information retrieved from the wearable devices through analysis of brain signal big data. With this big data, we predict and diagnose the stages of the neurological diseases such as Alzheimer’s disease and mild cognitive impairment.
36
Country: USA | Funding: $11M
We provide physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders.
We provide physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders.
37
Country: USA | Funding: $7.7M
Cerebrotech Medical Systems develops novel technologies for the non-invasive monitoring of patients after strokes and brain injuries.
Cerebrotech Medical Systems develops novel technologies for the non-invasive monitoring of patients after strokes and brain injuries.
38
Country: UK
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
39
Country: Israel | Funding: $4M
QuantalX NeuroScience develops first patient-independent active cerebral function imaging system that delivers a visual map of brain network health
QuantalX NeuroScience develops first patient-independent active cerebral function imaging system that delivers a visual map of brain network health
40
Country: Italy | Funding: €1.3M
BrainDTech represents a disruptive approach to brain disease diagnosis because it detects a signal (MicroRNA in microvesicles) released by microglia years before any clinical manifestation
BrainDTech represents a disruptive approach to brain disease diagnosis because it detects a signal (MicroRNA in microvesicles) released by microglia years before any clinical manifestation
41
Country: USA | Funding: $250K
Convalesce is a therapeutic company enabling stem cell-based therapy for neurodegenerative conditions like Parkinson's, harnessing state-of-art biomaterials.
Convalesce is a therapeutic company enabling stem cell-based therapy for neurodegenerative conditions like Parkinson's, harnessing state-of-art biomaterials.
42
Country: UK | Funding: $120K
We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences
We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences